MX2017014584A - Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. - Google Patents

Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.

Info

Publication number
MX2017014584A
MX2017014584A MX2017014584A MX2017014584A MX2017014584A MX 2017014584 A MX2017014584 A MX 2017014584A MX 2017014584 A MX2017014584 A MX 2017014584A MX 2017014584 A MX2017014584 A MX 2017014584A MX 2017014584 A MX2017014584 A MX 2017014584A
Authority
MX
Mexico
Prior art keywords
compounds
erk1
heterociclic
erk2
inhibitors
Prior art date
Application number
MX2017014584A
Other languages
English (en)
Other versions
MX388641B (es
Inventor
A Smith Roger
K Thompson Scott
Mulakala Chandrika
P Reddy Sanjeeva
M Dewang Purushottam
Hallur Gurulingappa
Reddy Kethiri Raghava
Mullangi Ramesh
Zainuddin Mohd
M Venkatesan Aranapakam
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of MX2017014584A publication Critical patent/MX2017014584A/es
Publication of MX388641B publication Critical patent/MX388641B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona nuevos compuestos heterocíclicos y sales farmacéuticamente aceptables de los mismos. También se proporcionan métodos para preparar estos compuestos. E stos compuestos son útiles para inhibir ERK1/2. Administrando a un paciente que necesita una cantidad terapéuticamente eficaz de uno o más de los compuestos de la fórmula (I), (ver Fórmula) en la que X, Y, Z, J, M y R1 a R8 se definen en la presente, estos compuestos son eficaces en el tratamiento de afecciones asociadas con la desregulación de la vía RAS/RAF/MEK/ERK. Se puede tratar una variedad de afecciones usando estos compuestos e incluyen enfermedades que se caracterizan por una proliferación celular anormal. En una modalidad, la enfermedad es cáncer.
MX2017014584A 2015-06-15 2016-06-15 Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. MX388641B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175756P 2015-06-15 2015-06-15
PCT/US2016/037697 WO2016205418A1 (en) 2015-06-15 2016-06-15 Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017014584A true MX2017014584A (es) 2018-02-26
MX388641B MX388641B (es) 2025-03-20

Family

ID=56497830

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014584A MX388641B (es) 2015-06-15 2016-06-15 Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX2021000148A MX2021000148A (es) 2015-06-15 2017-11-14 Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000148A MX2021000148A (es) 2015-06-15 2017-11-14 Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.

Country Status (18)

Country Link
US (5) US10751332B2 (es)
EP (2) EP3307727B1 (es)
JP (2) JP6909729B2 (es)
KR (2) KR102644798B1 (es)
CN (2) CN107922387B (es)
AU (2) AU2016280717C1 (es)
BR (1) BR112017026159A2 (es)
CA (1) CA2986587C (es)
DK (2) DK3307727T3 (es)
ES (2) ES2930050T3 (es)
FI (1) FI3307727T3 (es)
IL (1) IL255613B (es)
MX (2) MX388641B (es)
PL (2) PL3307727T3 (es)
PT (2) PT3842429T (es)
RU (1) RU2017139727A (es)
WO (1) WO2016205418A1 (es)
ZA (1) ZA201707526B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3307727T3 (pl) * 2015-06-15 2024-07-08 Asana Biosciences, Llc Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów
ES2989326T3 (es) 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
GB201706327D0 (en) * 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
AU2019280356B2 (en) * 2018-06-08 2022-09-29 Betta Pharmaceuticals Co., Ltd ERK inhibitor and use thereof
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
JP2022527744A (ja) 2019-03-28 2022-06-06 ジエンス ヘンルイ メデイシンカンパニー リミテッド チエノ複素環式誘導体、この誘導体のための調製方法及び医療に関するこの誘導体の使用
AU2020251621A1 (en) * 2019-03-29 2021-11-04 Jiangsu Hengrui Medicine Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
JP7738550B2 (ja) * 2019-10-28 2025-09-12 アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
AU2021354821A1 (en) * 2020-09-29 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
EP4322956A4 (en) * 2021-04-16 2025-03-19 Erasca, Inc. Uses of heterocyclic inhibitors of erk1/2
WO2022271919A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy
WO2022271939A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Erk1/2 and cdk4/6 inhibitors combination therapy
US20240285625A1 (en) * 2021-06-24 2024-08-29 Erasca, Inc. Erk1/2 and kras g12c inhibitors combination therapy
MX2023015298A (es) * 2021-06-24 2024-03-20 Erasca Inc Terapia de combinación de inhibidores de erk1/2 y shp2.
CN118871442A (zh) * 2022-03-28 2024-10-29 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的富马酸盐的晶型及其制备方法
WO2024064690A1 (en) * 2022-09-20 2024-03-28 Erasca, Inc. Erk1/2 inhibitor polymorph forms
EP4646209A1 (en) * 2023-01-06 2025-11-12 Erasca, Inc. Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319849B1 (it) 2000-02-18 2003-11-03 Angelo Dotta Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa.
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6743941B2 (en) 2001-06-15 2004-06-01 Aventis Pharma Deutschland Gmbh Process for the production of piperidine derivatives
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
EP1697375A2 (en) 2003-12-02 2006-09-06 Vertex Pharmaceuticals Incorporated Heterocyclic protein kinase inhibitors and uses thereof
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
WO2005113546A1 (en) * 2004-05-14 2005-12-01 Vertex Pharmaceuticals, Incorporated Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
EP1833820A1 (en) * 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinase and uses therof
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP5740409B2 (ja) * 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
US8691861B2 (en) 2011-04-13 2014-04-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
PL3307727T3 (pl) 2015-06-15 2024-07-08 Asana Biosciences, Llc Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów
CN109661228A (zh) 2016-06-20 2019-04-19 库拉肿瘤学公司 用erk抑制剂治疗鳞状细胞癌
TW202023556A (zh) 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
JP7738550B2 (ja) 2019-10-28 2025-09-12 アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン
EP4322956A4 (en) 2021-04-16 2025-03-19 Erasca, Inc. Uses of heterocyclic inhibitors of erk1/2

Also Published As

Publication number Publication date
JP2021105004A (ja) 2021-07-26
CN107922387B (zh) 2024-11-22
WO2016205418A1 (en) 2016-12-22
CA2986587C (en) 2024-03-12
JP2018517685A (ja) 2018-07-05
US20170362216A1 (en) 2017-12-21
AU2020273302A1 (en) 2020-12-17
JP6909729B2 (ja) 2021-07-28
ES2930050T3 (es) 2022-12-05
US11925629B2 (en) 2024-03-12
ES2968007T3 (es) 2024-05-06
PT3842429T (pt) 2022-11-21
US20230051842A1 (en) 2023-02-16
CN113200961B (zh) 2023-12-22
KR102644788B1 (ko) 2024-03-08
US9896445B2 (en) 2018-02-20
FI3307727T3 (fi) 2024-01-08
US10471051B2 (en) 2019-11-12
EP3842429A1 (en) 2021-06-30
US11103491B2 (en) 2021-08-31
US20160362406A1 (en) 2016-12-15
DK3842429T3 (da) 2022-11-07
AU2016280717B2 (en) 2020-12-03
US10751332B2 (en) 2020-08-25
BR112017026159A2 (pt) 2018-08-14
CA2986587A1 (en) 2016-12-22
IL255613A (en) 2018-01-31
PT3307727T (pt) 2024-01-12
EP3307727A1 (en) 2018-04-18
US20200179356A1 (en) 2020-06-11
JP7093438B2 (ja) 2022-06-29
EP3307727B1 (en) 2023-10-04
PL3842429T3 (pl) 2023-02-20
AU2016280717C1 (en) 2021-05-13
MX388641B (es) 2025-03-20
IL255613B (en) 2021-03-25
KR102644798B1 (ko) 2024-03-08
MX2021000148A (es) 2021-03-25
AU2016280717A1 (en) 2017-12-21
DK3307727T3 (da) 2024-01-08
EP3842429B1 (en) 2022-09-07
PL3307727T3 (pl) 2024-07-08
US20160362407A1 (en) 2016-12-15
KR20180014706A (ko) 2018-02-09
CN113200961A (zh) 2021-08-03
CN107922387A (zh) 2018-04-17
ZA201707526B (en) 2018-11-28
AU2020273302B2 (en) 2022-08-11
KR20210022160A (ko) 2021-03-02
RU2017139727A (ru) 2019-07-16

Similar Documents

Publication Publication Date Title
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2021009673A (es) Moduladores de ror-gamma.
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2015014387A (es) Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
GT201600123A (es) Inhibidores de syk
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
UY36207A (es) Inhibidores de la syk
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017011018A (es) Inhibicion de la actividad de olig2.
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.